NCT01121120TerminatedPhase 2
Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Tarix Pharmaceuticals10 sites in 1 country75 target enrollmentStarted: June 2010Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Enrollment
- 75
- Locations
- 10
- Primary Endpoint
- Platelet recovery
Study Overview
Brief Summary
The purpose of this study is to determine the safety and effectiveness of TXA127 in accelerating the time it takes for patients to recover their platelet counts following a Autologous Peripheral Blood Stem Cell transplant.
Detailed Description
- This is a randomized, double-blind (Investigator and Study Subject), placebo-controlled study.
- The conditioning regimen and mobilization agents used will be up to the discretion of the Study Center Investigator
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Supportive Care
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects must be at least 18 years of age
- •Subjects must have HL, NHL, or MM requiring PBSCT
- •Subjects must have a life expectancy of at least 4 months
- •Subjects are to receive autologous PBSC transplant following mobilization, CD34+ cells collected by apheresis, and conditioning chemotherapy
- •Subjects must give written informed consent to participate in study. Consent must be obtained prior to the performance of any study-specific, non-institutional standard procedures. A copy of the signed informed consent will be retained in the subject's chart.
- •Subjects must have CD34+ collection which allows reinfusion of ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg
- •Subjects must have a psychological and emotional state that, in the view of the investigators, allows adherence to the protocol
- •Female subjects capable of reproduction, and male subjects who have partners capable of reproduction, must agree to the following:
- •Use of an effective contraceptive method during the course of the study and for 2 months following the last administration of Investigational Product
- •Female subjects capable of reproduction must have a negative beta human chorionic gonadotropin (BHCG) serum or urine pregnancy test result within 7 days prior to first Investigational Product dose
- •Female subjects who are surgically sterilized or who have not experienced menses for at least two years are not required to have a pregnancy test
Exclusion Criteria
- •Subjects who have received radiotherapy to the pelvis and/or sternum within one year of first Investigational Product administration
- •Subjects who have previously received or have planned Total Body Irradiation (TBI)
- •Subjects with a history of prior malignancy other than HL, NHL, or MM that have not been in remission for >5 years, with the exception of basal cell or squamous cell carcinoma, cervical carcinoma in situ on biopsy, or localized prostate cancer (Gleason score <5)
- •Subjects with a history of myelodysplastic syndrome
- •Subjects who have had a venous or arterial embolic event AND who have received anti-coagulant treatment, where both the event and the treatment were within six months of the first Investigational Product administration
- •Prior allogeneic hematopoietic cell transplant
- •Presence of an uncontrolled infection or infection that required intravenous treatment within 7 days of entry
- •Female subjects who are pregnant or breastfeeding
- •Subjects who have received treatment with an investigational agent within 30 days of the projected first administration of Investigational Product (Day 0)
- •Subjects with current alcohol use, illicit drug use, or any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule
- •Subjects with a known sensitivity to any of the Investigational Product components
- •Subjects known to be seropositive for HIV or for HTLV-I
- •Subjects for whom prophylactic platelet transfusions, at platelet counts >10× 109/L, are anticipated following PBSC transplant
Arms & Interventions
TXA127
Experimental
300mcg/kg/day administered subcutaneously up to 28 days
Intervention: TXA127 (Drug)
Placebo
Placebo Comparator
300mcg/kg/day administered subcutaneously up to 28 days
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Platelet recovery
Time Frame: ≤ 28 days from re-infusion of CD34+ cells
Evaluate the effectiveness of TXA127 in accelerating the time to initial platelet recovery following PBSC transplant with a limited number of CD34+ cells, defined as CD34+ cell concentrations ≥1.5 x 106 and ≤5.0 x 106 CD34+ cells/kg. Platelet recovery is defined as that day the subject achieves a post-nadir platelet count of ≥20 x 109/L with no platelet transfusion in the prior 7 days.
Safety of TXA127
Time Frame: ≤ 28 days from re-infusion of CD34+ cells
Evaluate the safety of TXA127 administration following PBSC transplant
Secondary Outcomes
- Initial neutrophil recovery(≤ 28 days from re-infusion of CD34+ cells)
- Mucositis(≤ 28 days from re-infusion of CD34+ cells)
- Febrile neutropenia(≤ 28 days from re-infusion of CD34+ cells)
- Platelet transfusions(≤ 28 days from re-infusion of CD34+ cells)
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Terminated
Phase 1
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART TherapyHIV InfectionsNCT00757250US Biotest, Inc.13
Withdrawn
Phase 2
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood TransplantationHematologic MalignanciesNCT01882374Tarix Pharmaceuticals
Withdrawn
Phase 2
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationHematologic MalignanciesNCT01882387Tarix Pharmaceuticals
Terminated
Phase 2
ATX-101 in Advanced Dedifferentiated Liposarcoma and LeiomyosarcomaLeiomyosarcomaLiposarcomaNCT05116683Benjamin Izar4
Terminated
Phase 1
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood TransplantationDouble Cord Blood TransplantAcute Myelogenous LeukemiaChronic Myelocytic LeukemiaNon Hodgkins LymphomaHodgkins LymphomaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeMyelofibrosisNCT01300611Tarix Pharmaceuticals20